{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:24:53Z","timestamp":1789568693938,"version":"build-2803163510"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Changzhou Sci&Tech","award":["CJ.20230054"],"award-info":[{"award-number":["CJ.20230054"]}]},{"name":"Changzhou Sci&Tech","award":["CJ.20230054"],"award-info":[{"award-number":["CJ.20230054"]}]},{"name":"Changzhou Sci&Tech","award":["CJ.20230054"],"award-info":[{"award-number":["CJ.20230054"]}]},{"name":"Changzhou Sci&Tech","award":["CJ.20230054"],"award-info":[{"award-number":["CJ.20230054"]}]},{"name":"Changzhou Sci&Tech","award":["CJ.20230054"],"award-info":[{"award-number":["CJ.20230054"]}]},{"name":"the program of major science and technology project of changzhou health commission","award":["ZD.202101"],"award-info":[{"award-number":["ZD.202101"]}]},{"name":"the program of major science and technology project of changzhou health commission","award":["ZD.202101"],"award-info":[{"award-number":["ZD.202101"]}]},{"name":"the program of major science and technology project of changzhou health commission","award":["ZD.202101"],"award-info":[{"award-number":["ZD.202101"]}]},{"name":"the program of major science and technology project of changzhou health commission","award":["ZD.202101"],"award-info":[{"award-number":["ZD.202101"]}]},{"name":"the program of major science and technology project of changzhou health commission","award":["ZD.202101"],"award-info":[{"award-number":["ZD.202101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-024-04334-9","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T10:34:07Z","timestamp":1735554847000},"page":"1853-1863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Vitamin D: an important treatment for secondary hyperparathyroidism in chronic kidney disease?"],"prefix":"10.1007","volume":"57","author":[{"given":"Jie","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"4334_CR1","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","volume":"385","author":"T Liyanage","year":"2015","unstructured":"Liyanage T, Ninomiya T, Jha V, Neal B, Patrice HM, Okpechi I et al (2015) Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet Lond Engl 385:1975\u20131982","journal-title":"Lancet Lond Engl"},{"key":"4334_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamainternmed.2022.6817","volume":"183","author":"L Wang","year":"2023","unstructured":"Wang L, Xu X, Zhang M, Hu C, Zhang X, Li C et al (2023) Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance. JAMA Intern Med 183:298\u2013310","journal-title":"JAMA Intern Med"},{"key":"4334_CR3","doi-asserted-by":"crossref","unstructured":"Goodman WG, Quarles LD (2008) Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics. Kidney Int 74:276\u2013288. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815532997","DOI":"10.1038\/sj.ki.5002287"},{"key":"4334_CR4","doi-asserted-by":"publisher","unstructured":"Ronco C, Cozzolino M (2012) Mineral metabolism abnormalities and vitamin D receptor activation in cardiorenal syndromes. Heart Fail Rev 17:211\u2013220. https:\/\/doi.org\/10.1007\/s10741-011-9232-8","DOI":"10.1007\/s10741-011-9232-8"},{"key":"4334_CR5","doi-asserted-by":"publisher","unstructured":"Stevens PE (2013) Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice Guideline. Ann Intern Med 158:825. https:\/\/doi.org\/10.7326\/0003-4819-158-11-201306040-00007","DOI":"10.7326\/0003-4819-158-11-201306040-00007"},{"key":"4334_CR6","doi-asserted-by":"crossref","unstructured":"National Kidney Foundation (2003) K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:1\u2013201","DOI":"10.1016\/S0272-6386(03)00905-3"},{"key":"4334_CR7","doi-asserted-by":"crossref","unstructured":"Jean G, Charra B, Chazot C (2008) Vitamin D deficiency and associated factors in hemodialysis patients. J Ren Nutr 18:395\u2013399. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051227608002872","DOI":"10.1053\/j.jrn.2008.04.003"},{"key":"4334_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.5414\/CP203737","volume":"58","author":"M Li","year":"2020","unstructured":"Li M, Li Y (2020) Prevalence and influencing factors of vitamin D deficiency in chronic kidney disease: a cross-sectional study. Int J Clin Pharmacol Ther 58:595\u2013600","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4334_CR9","doi-asserted-by":"crossref","unstructured":"Nigwekar SU, Bhan I, Thadhani R (2012) Ergocalciferol and cholecalciferol in CKD. Am J Kidney Dis 60:139\u2013156. https:\/\/www.ajkd.org\/article\/S0272-6386(12)00636-1\/fulltext","DOI":"10.1053\/j.ajkd.2011.12.035"},{"key":"4334_CR10","doi-asserted-by":"publisher","unstructured":"Lindh JD, Bj\u00f6rkhem-Bergman L, Eliasson E (2012) Vitamin D and drug-metabolising enzymes. Photochem Photobiol Sci 11:1797\u20131801. https:\/\/doi.org\/10.1039\/c2pp25194a","DOI":"10.1039\/c2pp25194a"},{"key":"4334_CR11","doi-asserted-by":"publisher","unstructured":"Bikle DD (2012) Vitamin D and the skin: physiology and pathophysiology. Rev Endocr Metab Disord 13:3\u201319. https:\/\/doi.org\/10.1007\/s11154-011-9194-0","DOI":"10.1007\/s11154-011-9194-0"},{"key":"4334_CR12","doi-asserted-by":"crossref","unstructured":"Pignolo A, Mastrilli S, Dav\u00ec C, Arnao V, Aridon P, Dos Santos Mendes FA et al (2022) Vitamin D and Parkinson\u2019s disease. Nutrients 14:1220. https:\/\/www.mdpi.com\/2072-6643\/14\/6\/1220","DOI":"10.3390\/nu14061220"},{"key":"4334_CR13","doi-asserted-by":"crossref","unstructured":"Bikle DD, Patzek S, Wang Y (2018) Physiologic and pathophysiologic roles of extra renal CYP27b1: case report and review. Bone Rep 8:255\u2013267. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187218300093","DOI":"10.1016\/j.bonr.2018.02.004"},{"key":"4334_CR14","doi-asserted-by":"publisher","unstructured":"Dusso AS, Brown AJ, Slatopolsky E (2005) Vitamin D. Am J Physiol-Ren Physiol 289:F8\u2013F28. https:\/\/doi.org\/10.1152\/ajprenal.00336.2004","DOI":"10.1152\/ajprenal.00336.2004"},{"key":"4334_CR15","doi-asserted-by":"publisher","unstructured":"Kaur G, Singh J, Kumar J (2019) Vitamin D and cardiovascular disease in chronic kidney disease. Pediatr Nephrol 34:2509\u20132522. https:\/\/doi.org\/10.1007\/s00467-018-4088-y","DOI":"10.1007\/s00467-018-4088-y"},{"key":"4334_CR16","doi-asserted-by":"publisher","unstructured":"Zhu JG, Ochalek JT, Kaufmann M, Jones G, DeLuca HF (2013) CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc Natl Acad Sci 110:15650\u201315655. https:\/\/doi.org\/10.1073\/pnas.1315006110","DOI":"10.1073\/pnas.1315006110"},{"key":"4334_CR17","doi-asserted-by":"crossref","unstructured":"Zhu J, DeLuca HF (2012) Vitamin D 25-hydroxylase\u2014four decades of searching, are we there yet? Arch Biochem Biophys 523:30\u201336. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003986112000288","DOI":"10.1016\/j.abb.2012.01.013"},{"key":"4334_CR18","doi-asserted-by":"crossref","unstructured":"Delrue C, Speeckaert MM (2023) Vitamin D and vitamin D-binding protein in health and disease. Int J Mol Sci 24:4642. https:\/\/www.mdpi.com\/1422-0067\/24\/5\/4642","DOI":"10.3390\/ijms24054642"},{"key":"4334_CR19","doi-asserted-by":"crossref","unstructured":"Khammissa RAG, Fourie J, Motswaledi MH, Ballyram R, Lemmer J, Feller L (2018) The biological activities of vitamin D and its receptor in relation to calcium and bone homeostasis, cancer, immune and cardiovascular systems, skin biology, and oral health. BioMed Res Int 2018:1\u20139. https:\/\/www.hindawi.com\/journals\/bmri\/2018\/9276380\/","DOI":"10.1155\/2018\/9276380"},{"key":"4334_CR20","doi-asserted-by":"crossref","unstructured":"Delanghe JR, Speeckaert R, Speeckaert MM (2015) Behind the scenes of vitamin D binding protein: more than vitamin D binding. Best Pract Res Clin Endocrinol Metab 29:773\u2013786. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X15000676","DOI":"10.1016\/j.beem.2015.06.006"},{"key":"4334_CR21","doi-asserted-by":"crossref","unstructured":"(2005) K\/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 45:16\u2013153. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638605000922","DOI":"10.1053\/j.ajkd.2005.01.019"},{"key":"4334_CR22","doi-asserted-by":"publisher","unstructured":"Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK et al (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53\u201358. https:\/\/doi.org\/10.1210\/jc.2010-2704","DOI":"10.1210\/jc.2010-2704"},{"key":"4334_CR23","doi-asserted-by":"crossref","unstructured":"Berger MM, Shenkin A, Schweinlin A, Amrein K, Augsburger M, Biesalski H-K et al (2022) ESPEN micronutrient guideline. Clin Nutr 41:1357\u20131424. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561422000668","DOI":"10.1016\/j.clnu.2022.02.015"},{"key":"4334_CR24","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez EA, Sachdeva A, Oliver DA, Martin KJ (2004) Vitamin D insufficiency and deficiency in chronic kidney disease. Am J Nephrol 24:503\u2013510. https:\/\/www.karger.com\/Article\/FullText\/81023","DOI":"10.1159\/000081023"},{"key":"4334_CR25","doi-asserted-by":"crossref","unstructured":"Hsu H-J, Wu I-W, Hsu K-H, Sun C-Y, Chen C-Y, Lee C-C (2020) Vitamin D deficiency, cardiothoracic ratio, and long-term mortality in hemodialysis patients. Sci Rep 10:7533. https:\/\/www.nature.com\/articles\/s41598-020-64359-9","DOI":"10.1038\/s41598-020-64359-9"},{"key":"4334_CR26","doi-asserted-by":"crossref","unstructured":"Bhan I, Burnett-Bowie S-AM, Ye J, Tonelli M, Thadhani R (2010) Clinical measures identify vitamin D deficiency in dialysis. Clin J Am Soc Nephrol 5:460\u2013467. https:\/\/journals.lww.com\/01277230-201003000-00012","DOI":"10.2215\/CJN.06440909"},{"key":"4334_CR27","doi-asserted-by":"publisher","unstructured":"Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ (2002) Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann Neurol 52:168\u2013174. https:\/\/doi.org\/10.1002\/ana.10265","DOI":"10.1002\/ana.10265"},{"key":"4334_CR28","doi-asserted-by":"crossref","unstructured":"Taniguchi M, Tokumoto M, Matsuo D, Tsuruya K, Hirakata H, Iida M (2006) Parathyroid growth and regression in experimental uremia. Kidney Int 69:464\u2013470. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815515044","DOI":"10.1038\/sj.ki.5000090"},{"key":"4334_CR29","doi-asserted-by":"crossref","unstructured":"Cozzolino M, Ciceri P, Volpi EM, Olivi L, Messa PG (2009) Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease. Blood Purif 27:338\u2013344. https:\/\/www.karger.com\/Article\/FullText\/209246","DOI":"10.1159\/000209246"},{"key":"4334_CR30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000098561","volume":"27","author":"AL Zisman","year":"2007","unstructured":"Zisman AL, Hristova M, Ho LT, Sprague SM (2007) Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 27:36\u201343. https:\/\/doi.org\/10.1159\/000098561","journal-title":"Am J Nephrol"},{"key":"4334_CR31","doi-asserted-by":"crossref","unstructured":"Brandenburg V, Ketteler M (2022) Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future. Nutrients 14:3009. https:\/\/www.mdpi.com\/2072-6643\/14\/15\/3009","DOI":"10.3390\/nu14153009"},{"key":"4334_CR32","doi-asserted-by":"crossref","unstructured":"Brown AJ (2001) Therapeutic uses of vitamin D analogues. Am J Kidney Dis 38:S3\u2013S19. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638601787185","DOI":"10.1053\/ajkd.2001.28111"},{"key":"4334_CR33","doi-asserted-by":"crossref","unstructured":"Pinette K, Yee Y, Amegadzie B, Nagpal S (2003) Vitamin D receptor as a drug discovery target. Mini-Rev Med Chem 3:193\u2013204. http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1389-5575&volume=3&issue=3&spage=193","DOI":"10.2174\/1389557033488204"},{"key":"4334_CR34","doi-asserted-by":"crossref","unstructured":"Takahashi T, Morikawa K (2006) Vitamin D receptor agonists: opportunities and challenges in drug discovery. Curr Top Med Chem 6:1303\u20131316. http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1568-0266&volume=6&issue=12&spage=1303","DOI":"10.2174\/156802606777864917"},{"key":"4334_CR35","doi-asserted-by":"crossref","unstructured":"Eduardo-Canosa S, Fraga R, Sig\u00fceiro R, Marco M, Rochel N, Moras D et al (2010) Design and synthesis of active vitamin D analogs. J Steroid Biochem Mol Biol 121:7\u201312. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076010001275","DOI":"10.1016\/j.jsbmb.2010.03.036"},{"key":"4334_CR36","doi-asserted-by":"crossref","unstructured":"Boullata JI (2010) Vitamin D supplementation: a pharmacologic perspective: Curr Opin Clin Nutr Metab Care 13:677\u2013684. http:\/\/journals.lww.com\/00075197-201011000-00013","DOI":"10.1097\/MCO.0b013e32833de911"},{"key":"4334_CR37","doi-asserted-by":"crossref","unstructured":"Kittaka A, Saito N, Honzawa S, Takenouchi K, Ishizuka S, Chen TC et al (2007) Creative synthesis of novel vitamin D analogs for health and disease. J Steroid Biochem Mol Biol 103:269\u2013276. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076006003785","DOI":"10.1016\/j.jsbmb.2006.12.002"},{"key":"4334_CR38","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1080\/10408398.2021.1877110","volume":"62","author":"M Starek","year":"2022","unstructured":"Starek M, Mierzwa J, Gumu\u0142ka P, D\u0105browska M (2022) Vitamin D\u2014current stage of knowledge about analysis and supplementation. Crit Rev Food Sci Nutr 62:4607\u20134621. https:\/\/doi.org\/10.1080\/10408398.2021.1877110","journal-title":"Crit Rev Food Sci Nutr"},{"key":"4334_CR39","doi-asserted-by":"publisher","unstructured":"Armas LAG, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D 3 in humans. J Clin Endocrinol Metab 89:5387\u20135391. https:\/\/doi.org\/10.1210\/jc.2004-0360","DOI":"10.1210\/jc.2004-0360"},{"key":"4334_CR40","doi-asserted-by":"crossref","unstructured":"Heaney RP, Recker RR, Grote J, Horst RL, Armas LAG (2011) Vitamin D3 is more potent than vitamin D2 in humans. J Clin Endocrinol Metab 96:E447\u2013E452. https:\/\/academic.oup.com\/jcem\/article\/96\/3\/E447\/2597204","DOI":"10.1210\/jc.2010-2230"},{"key":"4334_CR41","doi-asserted-by":"crossref","unstructured":"Bouillon R, Verlinden L, Eelen G, De Clercq P, Vandewalle M, Mathieu C et al (2005) Mechanisms for the selective action of vitamin D analogs. J Steroid Biochem Mol Biol 97:21\u201330. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076005002384","DOI":"10.1016\/j.jsbmb.2005.06.013"},{"key":"4334_CR42","doi-asserted-by":"publisher","unstructured":"P\u00e9rez-Garc\u00eda X, Rumbo A, Larriba MJ, Ord\u00f3\u00f1ez P, Mu\u00f1oz A, Mouri\u00f1o A (2003) The first locked side-chain analogues of calcitriol (1\u03b1,25-Dihydroxyvitamin D3) induce vitamin D receptor transcriptional activity. Org Lett 5:4033\u20134036. https:\/\/doi.org\/10.1021\/ol0351246","DOI":"10.1021\/ol0351246"},{"key":"4334_CR43","doi-asserted-by":"publisher","unstructured":"Sig\u00fceiro R, Maestro MA, Mouri\u00f1o A (2018) Synthesis of side-chain locked analogs of 1\u03b1,25-dihydroxyvitamin D 3 bearing a C17 methyl group. Org Lett 20:2641\u20132644. https:\/\/doi.org\/10.1021\/acs.orglett.8b00849","DOI":"10.1021\/acs.orglett.8b00849"},{"key":"4334_CR44","doi-asserted-by":"publisher","unstructured":"Gogoi P, Seoane S, Sig\u00fceiro R, Guiberteau T, Maestro MA, P\u00e9rez-Fern\u00e1ndez R et al (2018) Aromatic-based design of highly active and noncalcemic vitamin D receptor agonists. J Med Chem 61:4928\u20134937. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b00337","DOI":"10.1021\/acs.jmedchem.8b00337"},{"key":"4334_CR45","doi-asserted-by":"publisher","unstructured":"Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ (1989) Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321:274\u2013279. https:\/\/doi.org\/10.1056\/NEJM198908033210502","DOI":"10.1056\/NEJM198908033210502"},{"key":"4334_CR46","doi-asserted-by":"publisher","unstructured":"Liao E-Y, Zhang Z-L, Xia W-B, Lin H, Cheng Q, Wang L et al (2018) Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium\/vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal. BMC Musculoskelet Disord 19:210. https:\/\/doi.org\/10.1186\/s12891-018-2090-y","DOI":"10.1186\/s12891-018-2090-y"},{"key":"4334_CR47","doi-asserted-by":"crossref","unstructured":"Kubodera N (2009) A new look at the most successful prodrugs for active vitamin D (D Hormone): alfacalcidol and doxercalciferol. Molecules 14:3869\u20133880. http:\/\/www.mdpi.com\/1420-3049\/14\/10\/3869","DOI":"10.3390\/molecules14103869"},{"key":"4334_CR48","doi-asserted-by":"crossref","unstructured":"Brown AJ, Slatopolsky E (2008) Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol Aspects Med 29:433\u2013452. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299708000186","DOI":"10.1016\/j.mam.2008.04.001"},{"key":"4334_CR49","doi-asserted-by":"crossref","unstructured":"Brown AJ (2007) Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? J Steroid Biochem Mol Biol 103:578\u2013583. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076006004559","DOI":"10.1016\/j.jsbmb.2006.12.089"},{"key":"4334_CR50","doi-asserted-by":"publisher","unstructured":"Mazzaferro S, Pasquali M, Conte C, Mandanici G, Muci ML, Lavini R (2009) Vitamin D receptor activators. Int J Artif Organs 32:101\u2013107. https:\/\/doi.org\/10.1177\/039139880903200207","DOI":"10.1177\/039139880903200207"},{"key":"4334_CR51","doi-asserted-by":"crossref","unstructured":"Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S et al (2006) Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47:263\u2013276. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638605015209","DOI":"10.1053\/j.ajkd.2005.10.007"},{"key":"4334_CR52","doi-asserted-by":"crossref","unstructured":"Park J, Rhee C, Lau W, Kalantar-Zadeh K (2014) Clinical uses of 1-alpha-hydroxy-ergocalciferol. Curr Vasc Pharmacol 12:306\u2013312. http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1570-1611&volume=12&issue=2&spage=306","DOI":"10.2174\/15701611113119990025"},{"key":"4334_CR53","doi-asserted-by":"crossref","unstructured":"Takahashi H, Ibe M, Kinouchi M, Ishida-Yamamoto A, Hashimoto Y, Iizuka H (2003) Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation. J Dermatol Sci 31:21\u201328. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923181102001366","DOI":"10.1016\/S0923-1811(02)00136-6"},{"key":"4334_CR54","doi-asserted-by":"crossref","unstructured":"Shintani T, Rosli SNZ, Takatsu F, Choon YF, Hayashido Y, Toratani S et al (2016) Eldecalcitol (ED-71), an analog of 1\u03b1,25-dihydroxyvitamin D3 as a potential anti-cancer agent for oral squamous cell carcinomas. J Steroid Biochem Mol Biol 164:79\u201384. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0960076015301023","DOI":"10.1016\/j.jsbmb.2015.09.043"},{"key":"4334_CR55","doi-asserted-by":"crossref","unstructured":"Kondo S, Takano T, Ono Y, Saito H, Matsumoto T (2015) Eldecalcitol reduces osteoporotic fractures by unique mechanisms. J Steroid Biochem Mol Biol 148:232\u2013238. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096007601500028X","DOI":"10.1016\/j.jsbmb.2015.01.016"},{"key":"4334_CR56","doi-asserted-by":"crossref","unstructured":"Harada S et al (2010) Eldecalcitol is less effective in suppressing parathyroid hormone compared to calcitriol in vivo. J Steroid Biochem Mol Biol 121:281\u2013283. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0960076010001913","DOI":"10.1016\/j.jsbmb.2010.04.001"},{"key":"4334_CR57","doi-asserted-by":"publisher","unstructured":"Sprague SM, Strugnell SA, Bishop CW (2017) Extended-release calcifediol for secondary hyperparathyroidism in stage 3\u20134 chronic kidney disease. Expert Rev Endocrinol Metab 12:289\u2013301. https:\/\/doi.org\/10.1080\/17446651.2017.1347501","DOI":"10.1080\/17446651.2017.1347501"},{"key":"4334_CR58","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000450766","volume":"44","author":"SM Sprague","year":"2016","unstructured":"Sprague SM, Crawford PW, Melnick JZ, Strugnell SA, Ali S, Mangoo-Karim R, Lee S, Petkovich PM, Bishop CW (2016) Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Am J Nephrol 44:316\u2013325. https:\/\/doi.org\/10.1159\/000450766","journal-title":"Am J Nephrol"},{"key":"4334_CR59","doi-asserted-by":"crossref","unstructured":"(2017) KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7:1\u201359. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171617300011","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"4334_CR60","doi-asserted-by":"crossref","unstructured":"Strugnell SA, Sprague SM, Ashfaq A, Petkovich M, Bishop CW (2019) Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease. Am J Nephrol 49:284\u2013293. https:\/\/www.karger.com\/Article\/FullText\/499187","DOI":"10.1159\/000499187"},{"key":"4334_CR61","doi-asserted-by":"publisher","first-page":"10","DOI":"10.4158\/EP.14.1.10","volume":"14","author":"P Chandra","year":"2008","unstructured":"Chandra P, Binongo JNG, Ziegler TR, Schlanger LE, Wang W, Someren JT, Tangpricha V (2008) Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 14:10\u201317. https:\/\/doi.org\/10.4158\/EP.14.1.10","journal-title":"Endocr Pract"},{"key":"4334_CR62","doi-asserted-by":"crossref","unstructured":"Sprague SM, Silva AL, Al-Saghir F, Damle R, Tabash SP, Petkovich M et al (2014) Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease. Am J Nephrol 40:535\u2013545. https:\/\/www.karger.com\/Article\/FullText\/369939","DOI":"10.1159\/000369939"},{"key":"4334_CR63","doi-asserted-by":"crossref","unstructured":"Bover J, Gunnarsson J, Csomor P, Kaiser E, Cianciolo G, Lauppe R (2021) Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis. Clin Kidney J 14:2177\u20132186. https:\/\/academic.oup.com\/ckj\/article\/14\/10\/2177\/6129095","DOI":"10.1093\/ckj\/sfab035"},{"key":"4334_CR64","doi-asserted-by":"publisher","unstructured":"Agarwal R, Georgianos PI (2016) Con: nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease. Nephrol Dial Transp 31:706\u2013713. https:\/\/doi.org\/10.1093\/ndt\/gfw080","DOI":"10.1093\/ndt\/gfw080"},{"key":"4334_CR65","doi-asserted-by":"crossref","unstructured":"Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM (2014) A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3\u20134 CKD. Clin J Am Soc Nephrol 9:1620\u20131626. https:\/\/journals.lww.com\/01277230-201409000-00018","DOI":"10.2215\/CJN.10661013"},{"key":"4334_CR66","first-page":"319","volume":"53","author":"HH Liou","year":"1994","unstructured":"Liou HH, Chiang SS, Tsai SC, Chang CC, Wu SC, Shieh SD et al (1994) Effect of intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Zhonghua Yi Xue Za Zhi Chin Med J Free China Ed 53:319\u2013324","journal-title":"Zhonghua Yi Xue Za Zhi Chin Med J Free China Ed"},{"key":"4334_CR67","unstructured":"Delmez JA, Kelber J, Norwood KY, Giles KS, Slatopolsky E (2000) A controlled trial of the early treatment of secondary hyperparathyroidism with calcitriol in hemodialysis patients. Clin Nephrol 54. https:\/\/pubmed.ncbi.nlm.nih.gov\/11076106\/"},{"key":"4334_CR68","first-page":"167","volume":"52","author":"D Grekas","year":"1999","unstructured":"Grekas D, Balaskas E, Kampouris H, Benos A, Konstantinou A, Sioullis A et al (1999) Effective treatment of secondary hyperparathyroidism in hemodialysis patients by titration of intravenous calcitriol dosage. Clin Nephrol 52:167\u2013171","journal-title":"Clin Nephrol"},{"key":"4334_CR69","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhao M-H, Zuo L, Wang Y, Yu F, Zhang H et al (2020) China kidney disease network (CK-NET) 2016 annual data report. Kidney Int Suppl 10:e97\u2013e185. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2157171620300228","DOI":"10.1016\/j.kisu.2020.09.001"},{"key":"4334_CR70","doi-asserted-by":"crossref","unstructured":"Shoben AB, Rudser KD, De Boer IH, Young B, Kestenbaum B (2008) Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 19:1613\u20131619. https:\/\/journals.lww.com\/00001751-200808000-00024","DOI":"10.1681\/ASN.2007111164"},{"key":"4334_CR71","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1440-1797.2010.01398.x","volume":"16","author":"K Kiattisunthorn","year":"2011","unstructured":"Kiattisunthorn K, Wutyam K, Indranoi A, Vasuvattakul S (2011) Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients. Nephrol Carlton Vic 16:277\u2013284","journal-title":"Nephrol Carlton Vic"},{"key":"4334_CR72","doi-asserted-by":"publisher","unstructured":"Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, Strippoli GFM (2007) Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147:840. https:\/\/doi.org\/10.7326\/0003-4819-147-12-200712180-00004","DOI":"10.7326\/0003-4819-147-12-200712180-00004"},{"key":"4334_CR73","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1681\/ASN.V981427","volume":"9","author":"KJ Martin","year":"1998","unstructured":"Martin KJ, Gonz\u00e1lez EA, Gellens M, Hamm LL, Abboud H, Lindberg J (1998) 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol JASN 9:1427\u20131432","journal-title":"J Am Soc Nephrol JASN"},{"key":"4334_CR74","doi-asserted-by":"publisher","unstructured":"Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H et al (2012) Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307:674. https:\/\/doi.org\/10.1001\/jama.2012.120","DOI":"10.1001\/jama.2012.120"},{"key":"4334_CR75","doi-asserted-by":"crossref","unstructured":"Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483\u20131490. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815490271","DOI":"10.1046\/j.1523-1755.2003.00878.x"},{"key":"4334_CR76","doi-asserted-by":"publisher","unstructured":"Sprague SM, Lerma E, McCormmick D, Abraham M, Battle D (2001) Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol. Am J Kidney Dis 38:S51\u2013S56. https:\/\/doi.org\/10.1053\/ajkd.2001.28110.","DOI":"10.1053\/ajkd.2001.28110"},{"key":"4334_CR77","doi-asserted-by":"publisher","first-page":"712027","DOI":"10.3389\/fpubh.2021.712027","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Cai L, Wu H, Xu X, Fang W, He X, Wang X, Li X (2021) Paricalcitol versus calcitriol + cinacalcet for the treatment of secondary hyperparathyroidism in chronic kidney disease in China: a cost-effectiveness analysis. Front Public Health 9:712027. https:\/\/doi.org\/10.3389\/fpubh.2021.712027","journal-title":"Front Public Health"},{"key":"4334_CR78","first-page":"315","volume":"56","author":"J Lindberg","year":"2001","unstructured":"Lindberg J, Martin KJ, Gonz\u00e1lez EA, Acchiardo SR, Valdin JR, Soltanek C (2001) A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 56:315\u2013323","journal-title":"Clin Nephrol"},{"key":"4334_CR79","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000092033","volume":"26","author":"H Abboud","year":"2006","unstructured":"Abboud H, Coyne D, Smolenski O, Anger M, Lunde N, Qiu P et al (2006) A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4. Am J Nephrol 26:105\u2013114","journal-title":"Am J Nephrol"},{"key":"4334_CR80","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/ndt\/13.5.1234","volume":"13","author":"SM Moe","year":"1998","unstructured":"Moe SM, Kraus MA, Gassensmith CM, Fineberg NS, Gannon FH, Peacock M (1998) Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial. Nephrol Dial Transplant 13:1234\u20131241","journal-title":"Nephrol Dial Transplant"},{"key":"4334_CR81","doi-asserted-by":"crossref","unstructured":"Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM et al (2004) Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 43:877\u2013890. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638604001416","DOI":"10.1053\/j.ajkd.2004.01.012"},{"key":"4334_CR82","doi-asserted-by":"crossref","unstructured":"Baker LRI, Abrams SML, Roe CJ, Faugere M-C, Fanti P, Subayti Y et al (1989) 1,25(OH)2D3 administration in moderate renal failure: a prospective double-blind trial. Kidney Int 35:661\u2013669. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381534477X","DOI":"10.1038\/ki.1989.36"},{"key":"4334_CR83","doi-asserted-by":"publisher","unstructured":"Nordal KP, Dahl E (1988) Low dose calcitriol versus placebo in patients with predialysis chronic renal failure*. J Clin Endocrinol Metab 67:929\u2013936. https:\/\/doi.org\/10.1210\/jcem-67-5-929","DOI":"10.1210\/jcem-67-5-929"},{"key":"4334_CR84","doi-asserted-by":"crossref","unstructured":"Cozzolino M, Bernard L, Csomor PA (2021) Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. Clin Kidney J 14:2437\u20132443. https:\/\/academic.oup.com\/ckj\/article\/14\/11\/2437\/6287651","DOI":"10.1093\/ckj\/sfab091"},{"key":"4334_CR85","doi-asserted-by":"crossref","unstructured":"Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B et al (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520\u2013528. https:\/\/journals.lww.com\/00001751-200502000-00034","DOI":"10.1681\/ASN.2004070602"},{"key":"4334_CR86","doi-asserted-by":"crossref","unstructured":"Block GA, Port FK (2000) Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 35:1226\u20131237. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638600700643","DOI":"10.1016\/S0272-6386(00)70064-3"},{"key":"4334_CR87","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1111\/j.1523-1755.2005.67103.x","volume":"67","author":"M Colloton","year":"2005","unstructured":"Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D et al (2005) Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 67:467\u2013476","journal-title":"Kidney Int"},{"key":"4334_CR88","doi-asserted-by":"publisher","unstructured":"Shigematsu T, Asada S, Endo Y, Kawata T, Fukagawa M, Akizawa T (2022) Evocalcet with vitamin D receptor activator treatment for secondary hyperparathyroidism. Barretti P, editor. PLOS ONE 17:e0262829. https:\/\/doi.org\/10.1371\/journal.pone.0262829","DOI":"10.1371\/journal.pone.0262829"},{"key":"4334_CR89","doi-asserted-by":"publisher","unstructured":"Mizobuchi M, Ogata H, Koiwa F (2019) Secondary hyperparathyroidism: pathogenesis and latest treatment. Ther Apher Dial 23:309\u2013318. https:\/\/doi.org\/10.1111\/1744-9987.12772","DOI":"10.1111\/1744-9987.12772"},{"key":"4334_CR90","doi-asserted-by":"crossref","unstructured":"Torres PU (2006) Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. J Ren Nutr 16:253\u2013258. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1051227606000914","DOI":"10.1053\/j.jrn.2006.04.010"},{"key":"4334_CR91","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-012-0665-8","volume":"17","author":"Y Tsuruta","year":"2013","unstructured":"Tsuruta Y, Okano K, Kikuchi K, Tsuruta Y, Akiba T, Nitta K (2013) Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol 17:120\u2013126","journal-title":"Clin Exp Nephrol"},{"key":"4334_CR92","doi-asserted-by":"crossref","unstructured":"EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Dr\u00fceke TB, Floege J et al (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482\u20132494","DOI":"10.1056\/NEJMoa1205624"},{"key":"4334_CR93","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","volume":"132","author":"SM Moe","year":"2015","unstructured":"Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R et al (2015) Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 132:27\u201339","journal-title":"Circulation"},{"key":"4334_CR94","doi-asserted-by":"publisher","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K et al (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26:1327\u20131339. https:\/\/doi.org\/10.1093\/ndt\/gfq725","DOI":"10.1093\/ndt\/gfq725"},{"key":"4334_CR95","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000484435","volume":"45","author":"F Yuan","year":"2018","unstructured":"Yuan F, Chen X, Wang C, Li Z, Liu H (2018) Effect of cinacalcet combined with calcitriol on the clinical outcome and bone metabolism in patients on hemodialysis with severe secondary hyperparathyroidism. Blood Purif 45:73\u201378","journal-title":"Blood Purif"},{"key":"4334_CR96","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1056\/NEJMoa031633","volume":"350","author":"GA Block","year":"2004","unstructured":"Block GA, Martin KJ, de Francisco ALM, Turner SA, Avram MM, Suranyi MG et al (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516\u20131525","journal-title":"N Engl J Med"},{"key":"4334_CR97","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s40620-019-00686-z","volume":"33","author":"KS Louie","year":"2020","unstructured":"Louie KS, Erhard C, Wheeler DC, Stenvinkel P, Fouqueray B, Floege J (2020) Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes. J Nephrol 33:803\u2013816","journal-title":"J Nephrol"},{"key":"4334_CR98","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.2215\/CJN.13081211","volume":"7","author":"M Fukagawa","year":"2012","unstructured":"Fukagawa M, Fukuma S, Onishi Y, Yamaguchi T, Hasegawa T, Akizawa T et al (2012) Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Clin J Am Soc Nephrol 7:1473\u20131480","journal-title":"Clin J Am Soc Nephrol"},{"key":"4334_CR99","doi-asserted-by":"crossref","unstructured":"Fishbane S, Shapiro WB, Corry DB, Vicks SL, Roppolo M, Rappaport K et al (2008) Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 3:1718\u20131725. https:\/\/journals.lww.com\/01277230-200811000-00020","DOI":"10.2215\/CJN.01040308"},{"key":"4334_CR100","doi-asserted-by":"publisher","unstructured":"Sharma A, Marshall TS, Khan SS, Johns B (2014) Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA. Clin Drug Investig 34:107\u2013115. https:\/\/doi.org\/10.1007\/s40261-013-0151-4","DOI":"10.1007\/s40261-013-0151-4"},{"key":"4334_CR101","doi-asserted-by":"crossref","unstructured":"Shroff R, Egerton M, Bridel M, Shah V, Donald AE, Cole TJ et al (2008) A bimodal association of vitamin D levels and vascular disease in children on dialysis. J Am Soc Nephrol 19:1239\u20131246. https:\/\/journals.lww.com\/00001751-200806000-00027","DOI":"10.1681\/ASN.2007090993"},{"key":"4334_CR102","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000346846","volume":"37","author":"F Duranton","year":"2013","unstructured":"Duranton F, Rodriguez-Ortiz ME, Duny Y, Rodriguez M, Daur\u00e8s J-P, Argil\u00e9s A (2013) Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol 37:239\u2013248","journal-title":"Am J Nephrol"},{"key":"4334_CR103","doi-asserted-by":"crossref","unstructured":"Wolf M, Thadhani R (2007) Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J Steroid Biochem Mol Biol 103:487\u2013490. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076006003566","DOI":"10.1016\/j.jsbmb.2006.11.009"},{"key":"4334_CR104","doi-asserted-by":"publisher","unstructured":"Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446\u2013456. https:\/\/doi.org\/10.1056\/NEJMoa022536","DOI":"10.1056\/NEJMoa022536"},{"key":"4334_CR105","doi-asserted-by":"publisher","unstructured":"Dobrez DG, Mathes A, Amdahl M, Marx SE, Melnick JZ, Sprague SM (2004) Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 19:1174\u20131181. https:\/\/doi.org\/10.1093\/ndt\/gfh123","DOI":"10.1093\/ndt\/gfh123"},{"key":"4334_CR106","doi-asserted-by":"crossref","unstructured":"Dreyer G, Tucker AT, Harwood SM, Pearse RM, Raftery MJ, Yaqoob MM (2014) Ergocalciferol and microcirculatory function in chronic kidney disease and concomitant vitamin d deficiency: an exploratory, double blind, randomised controlled trial. PloS One 9. https:\/\/pubmed.ncbi.nlm.nih.gov\/25006678\/","DOI":"10.1371\/journal.pone.0099461"},{"key":"4334_CR107","doi-asserted-by":"crossref","unstructured":"Zittermann A, Koerfer R (2008) Protective and toxic effects of vitamin D on vascular calcification: clinical implications. Mol Aspects Med 29:423\u2013432. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0098299708000174","DOI":"10.1016\/j.mam.2008.04.002"},{"key":"4334_CR108","doi-asserted-by":"crossref","unstructured":"Li YC, Kong J, Wei M, Chen Z-F, Liu SQ, Cao L-P (2002) 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229\u2013238. http:\/\/www.jci.org\/articles\/view\/15219","DOI":"10.1172\/JCI15219"},{"key":"4334_CR109","doi-asserted-by":"crossref","unstructured":"Card\u00fas A, Parisi E, Gallego C, Aldea M, Fern\u00e1ndez E, Valdivielso JM (2006) 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 69:1377\u20131384. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815516797","DOI":"10.1038\/sj.ki.5000304"},{"key":"4334_CR110","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10157-009-0233-z","volume":"14","author":"S Sugiura","year":"2010","unstructured":"Sugiura S, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Sendo S et al (2010) Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Clin Exp Nephrol 14:43\u201350","journal-title":"Clin Exp Nephrol"},{"key":"4334_CR111","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/ndt\/gfg595","volume":"19","author":"M Rix","year":"2004","unstructured":"Rix M, Eskildsen P, Olgaard K (2004) Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 19:870\u2013876","journal-title":"Nephrol Dial Transplant"},{"key":"4334_CR112","doi-asserted-by":"crossref","unstructured":"Ruedin P, Rizzoli R, Slosman D, Leski M, Bonjour J-P (1994) Effects of oral calcitriol on bone mineral density in patients with end-stage renal failure. Kidney Int 45:245\u2013252. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S008525381558304X","DOI":"10.1038\/ki.1994.30"},{"key":"4334_CR113","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","volume":"310","author":"NA Hamdy","year":"1995","unstructured":"Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG et al (1995) Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310:358\u2013363","journal-title":"BMJ"},{"key":"4334_CR114","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","volume":"68","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P et al (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823\u20132828","journal-title":"Kidney Int"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04334-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-024-04334-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-024-04334-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T14:12:57Z","timestamp":1746281577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-024-04334-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":114,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["4334"],"URL":"https:\/\/doi.org\/10.1007\/s11255-024-04334-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}